LINAPRIDE DM 1000

About

This medication combines linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with metformin, a biguanide, to offer a comprehensive approach to glycemic control in adults with type 2 diabetes mellitus. Linagliptin works by enhancing the body's natural ability to lower high blood glucose levels; it achieves this by increasing active incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. Metformin, on the other hand, primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. The synergistic action of these two agents addresses multiple pathophysiological defects inherent in type 2 diabetes, leading to significant reductions in HbA1c levels. This combination is typically used as an adjunct to diet and exercise when monotherapy with either agent is insufficient or when initial therapy requires a dual approach.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control.
• Used when diet and exercise alone are insufficient.
• Used when monotherapy with linagliptin or metformin is inadequate.

Directions For Use

Take orally, usually twice daily with meals, as prescribed by your doctor.

Benefits

• Dual mechanism of action for enhanced glycemic control.
• Significant reduction in HbA1c levels.
• Potential for weight loss or weight neutrality.
• Reduced risk of cardiovascular events (metformin).
• Improved insulin sensitivity.
• Convenient fixed-dose combination.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Vomiting
• Metallic taste
• Headache
• Nasopharyngitis
• Hypoglycemia (especially with other agents)
• Lactic acidosis (rare, but serious with metformin)
• Vitamin B12 deficiency (with long-term metformin use)
• Pancreatitis (rare, linagliptin component)
• Joint pain

Safety Measures

• Alcohol - Avoid excessive alcohol intake, as it can increase the risk of lactic acidosis with metformin and affect blood sugar.
• Pregnancy - Not recommended; insulin is generally preferred for glycemic control during pregnancy.
• Breastfeeding - Metformin is excreted in breast milk; linagliptin excretion is unknown. Consult a physician.
• Liver - Use with caution in patients with hepatic impairment due to increased risk of lactic acidosis with metformin.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to metformin accumulation and lactic acidosis risk.
• Lung - Use with caution in severe acute or chronic lung disease due to potential for hypoxia, increasing lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.